GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (NAS:REGN) » Definitions » Buyback Yield %

Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Buyback Yield % : 1.85 (As of Apr. 27, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Regeneron Pharmaceuticals Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Regeneron Pharmaceuticals's current buyback yield was 1.85%.


Regeneron Pharmaceuticals Buyback Yield % Historical Data

The historical data trend for Regeneron Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Buyback Yield % Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 7.65 1.47 1.28 1.86

Regeneron Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 1.43 3.14 1.82 1.86

Competitive Comparison of Regeneron Pharmaceuticals's Buyback Yield %

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Buyback Yield % falls into.



Regeneron Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Regeneron Pharmaceuticals's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-2935.6 + 1145.5) / 96100.73522
=1.86%

Regeneron Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (-747.1 + 301) * 4 / 96100.73522
=1.86%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Dec. 2023) data.


Regeneron Pharmaceuticals Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Executives
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Arthur F Ryan director CITIZENS FINANCIAL GROUP, INC, 600 WASHINGTON BOULEVARD, STAMFORD CT 06901
George Yancopoulos director, officer: President and CSO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Huda Y Zoghbi director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Marion Mccourt officer: SVP Commercial C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael S Brown director
Christopher R. Fenimore officer: VP, Controller REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Andrew J Murphy officer: EVP Research REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Kathryn Guarini director 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
David P Schenkein director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Van Plew Daniel P officer: EVP & General Mgr Industrial O REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Robert E Landry officer: SVP Fin, Dep CFO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Neil Stahl officer: SVP, Preclinical Development 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph L Goldstein director DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS, 5323 HARRY HINES BLVD, DALLAS TX 75390